3 completed. 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 2 | Completed 2 |
Follow Hepatomegaly: new trials by email Literature Review of Hepatomegaly trials Research Report on Hepatomegaly
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis Isatuximab, Laboratory Biomarker Analysis - Amorphous, Eosinophilic, and Acellular Deposit, Constipation | Phase 2 | Completed | SWOG Cancer Research Network | 43 | 2018-06-06 | 2025-09-09 |
| Lanreotide as Treatment of Polycystic Livers Placebo, Lanreotide - Polycystic Liver Disease, Hepatomegaly | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 38 | 2007-10-01 | 2009-02-17 |
| Octreotide in Severe Polycystic Liver Disease Octreotide, Placebo - Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease | Phase 2 / Phase 3 | Completed | Mayo Clinic | 42 | 2007-01-01 | 2012-11-21 |
Liver Diseases (2) · Polycystic Kidney, Autosomal Dominant (2) · Polycystic liver disease (2) · Abdominal Pain (1) · Constipation (1) · Diarrhea (1) · Gastrointestinal Hemorrhage (1) · Immunoglobulin Light-chain Amyloidosis (1) · Lymphadenopathy (1) · Macroglossia (1) · Nausea (1) · Polycystic Kidney Diseases (1) · Purpura (1)
Digestive System Diseases (3) · Hypertrophy (3) · Pathological Conditions, Anatomical (3) · Pathological Conditions, Signs and Symptoms (3) · Abnormalities, Multiple (2) · Ciliopathies (2) · Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genetic Diseases, Inborn (2) · Kidney Diseases (2) · Kidney Diseases, Cystic (2) · Male Urogenital Diseases (2) · Signs and Symptoms (2)
Octreotide (1) · isatuximab (1) · lanreotide (1)
Mayo Clinic (1) · Radboud University Medical Center (1) · SWOG Cancer Research Network (1)
United States (2) · Belgium (1) · Netherlands (1)
Emma Scott (1) · Frederik Nevens, MD, PhD (1) · Joost PH Drenth, MD, PhD (1) · Loes van Keimpema, MSc (1) · Marie C. Hogan, M.D., Ph.D. (1)
PMID 39356039, PMID 22773240, PMID 26166166, PMID 40925099
U10CA180888 (1), UL1RR024150 (1)